Ambu A/S: Capital increase in connection with exercise of warrants issued
Ambu A/S: Capital increase in connection with exercise of warrants issued
Ambu A/S issued 419,500 warrants in 2016. Each warrant entitled the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 71 individuals participated in the 2016 scheme.
Ambu A/S在2016年发行了41.95万份权证。每份认股权证持有人有权认购一股面值为0.50丹麦克朗的B类股票。71人参与了2016年的计划。
For the 2016 scheme the vesting period was three years, and the scheme could therefore be exercised in the trading window that opened on 8 February 2022 in connection with Ambu's interim financial report for Q1 2021/22.
对于2016年计划，归属期限为三年，因此该计划可以在2022年2月8日开放的交易窗口中与Ambu的2021/22年第一季度中期财务报告相关的交易窗口中行使。
Since 8 February 2022, instructions have been received to exercise warrants as follows:
自2022年2月8日以来，已收到如下行使认股权证的指示：
- 2 individuals have issued instructions to exercise 7,500 warrants at the agreed exercise price of DKK 77.12 per share with a nominal value of DKK 0.50.
- 2名个人已发出指示，将按商定的行权价每股77.12丹麦克朗行使7500份认股权证，票面价值为0.50丹麦克朗。
Today Ambu's Board of Directors decided to carry out the capital increase relating to the exercised warrants.
今天，Ambu董事会决定对已行使的认股权证进行增资。
As a result of the capital increase, the share capital of the Company's B shares will be increased by a nominal amount of DKK 3,750 from DKK 111,694,466 to DKK 111,698,216 through the issue of 7,500 Class B shares.
增资后，公司B股股本将通过发行7,500股B类股，增加面值3,750丹麦克朗，由111,694,466丹麦克朗增至111,698,216丹麦克朗。
Following this and in consideration of the employees having left the company, the following warrants remain under the said 2016 scheme:
在此之后，考虑到员工已经离开公司，根据上述2016年的计划，以下认股权证仍然存在：
- 169,500 warrants being held by 25 individuals.
- 169,500份认股权证由25名个人持有。
The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 22 February 2022 under the ISIN code of Ambu A/S' existing B shares (DK0060946788).
预计新发行的B股将于2022年2月22日获准在纳斯达克哥本哈根A/S交易并正式挂牌，交易代码为安步A/S现有B股ISIN码(DK0060946788)。
Under section 32 of the Danish Capital Markets Act, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.
根据丹麦资本市场法第32条，Ambu A/S应在股本发生任何变化的一个月结束前公布总股本和总投票权。下表显示了增资后Ambu A/S的总股本和总投票权。
| Number of shares (nominal value DKK 0.50) |
Nominal value (DKK) |
Voting rights | |
| A shares | 34,320,000 | 17,160,000 | 343,200,000 |
| B shares | 223,396,432 | 111,698,216 | 223,396,432 |
| Total | 257,716,432 | 128,858,216 | 566,596,432 |
| 股份数量 (名义价值0.50丹麦克朗) |
名义价值 (DKK) |
投票权 | |
| A股 | 34,320,000 | 17,160,000 | 343,200,000 |
| B股 | 223,396,432 | 111,698,216 | 223,396,432 |
| 总计 | 257,716,432 | 128,858,216 | 566,596,432 |
Contact
联系人
Michael Højgaard, CFO, miho@ambu.com / +45 4030 4349
电子邮件：miho@ambu.com/+45 4030 4349
Ambu A/S
Baltorpbakken 13, DK-2750 Ballerup, Denmark, Tel.: +45 7225 2000, CVR no.: 63 64 49 19,
Ambu A/S
Baltorpbakken 13，DK-2750 Ballup，丹麦，电话：+45 7225 2000，电话：+45 7225 2000，CVR号码：63 64 49 19，
About Ambu
Ambu has been bringing the solutions of the future to life since 1937. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring & diagnostics solutions. The manifestations of our efforts have ranged from early innovations like the Ambu® Bag™ resuscitator and the Ambu® BlueSensor™ electrodes to our newest landmark solutions like the Ambu® aScope™ – the world's first single-use flexible endoscope. Moreover, we continuously look to the future with a commitment to deliver innovative quality products that have a positive impact on the work of doctors, nurses and paramedics. Headquartered near Copenhagen in Denmark, Ambu employs approximately 4,500 people in Europe, North America and the Asia Pacific. For more information, please visit ambu.com.
关于Ambu
自1937年以来，Ambu一直在将未来的解决方案带入生活。今天，全球数以百万计的患者和医疗保健专业人员依赖于我们的一次性内窥镜检查、麻醉以及患者监控和诊断解决方案的效率、安全性和性能。我们的努力体现了从早期的创新(如AMBU®BAG™复苏器和AMBU®BlueSensor™电极)到我们最新的标志性解决方案，如AMBU®AScope™(全球首款一次性使用的柔性内窥镜)。此外，我们继续展望未来，致力于提供对医生、护士和护理人员的工作产生积极影响的创新高质量产品。Ambu总部位于丹麦哥本哈根附近，在欧洲、北美和亚太地区拥有约4500名员工。欲了解更多信息，请访问ambu.com。
Attachment
依附
- Company-announcement-no-7_2021-22
- 公司-公告-编号-7_2021-22
译文内容由第三方软件翻译。